Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Ravulizumab in ALS Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. A diagnosis of sporadic or familial ALS, defined by the El Escorial criteria (possible, laboratory-supported probable, probable, or definite ALS).~2. ALS onset ≤ 36 months from Screening.~3. Documented meningococcal vaccination not more than 3 years prior to, or at the time of, initiating study treatment.~4. Upright slow vital capacity ≥ 65% predicted at Screening.~5. If on riluzole, participant must be on a stable dose for 30 days; if on edaravone, participant must be on a stable dose for 60 days (2 cycles).~6. Body weight ≥ 40 kilograms at Screening.~7. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.~Key Exclusion Criteria:~1. History of Neisseria meningitidis infection.~2. Human immunodeficiency virus (HIV) infection (evidenced by HIV 1 or HIV 2 antibody titer).~3. Dependence on invasive or non-invasive mechanical ventilation.~4. Previously or currently treated with a complement inhibitor.~5. Exposure to an investigational drug or device within 30 days of Screening or 5 half lives of the study drug, whichever is greater.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ravulizumab (Type: EXPERIMENTAL): Participants will receive ravulizumab for the duration of the study.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo during the 50-week Randomized Controlled Period of the study, after which they will enter the Open-label Extension Period of the study and switch to receive ravulizumab.

Based on this trial design, predict the completion outcome and termination type (if applicable).